Free Trial

Solventum (SOLV) Stock Forecast & Price Target

Solventum logo
$70.81 +1.18 (+1.69%)
(As of 11/22/2024 ET)

Solventum - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
8
Buy
1

Based on 10 Wall Street analysts who have issued ratings for Solventum in the last 12 months, the stock has a consensus rating of "Hold." Out of the 10 analysts, 1 has given a sell rating, 8 have given a hold rating, and 1 has given a buy rating for SOLV.

Consensus Price Target

$68.00
-3.97% Downside
According to the 10 analysts' twelve-month price targets for Solventum, the average price target is $68.00. The highest price target for SOLV is $82.00, while the lowest price target for SOLV is $54.00. The average price target represents a forecasted downside of -3.97% from the current price of $70.81.
Get the Latest News and Ratings for SOLV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Solventum and its competitors.

Sign Up

SOLV Analyst Ratings Over Time

TypeCurrent Forecast
11/24/23 to 11/23/24
1 Month Ago
10/25/23 to 10/24/24
3 Months Ago
8/26/23 to 8/25/24
1 Year Ago
11/24/22 to 11/24/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
0 Buy rating(s)
N/A
Hold
8 Hold rating(s)
8 Hold rating(s)
5 Hold rating(s)
N/A
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
N/A
Consensus Price Target$68.00$64.33$58.25N/A
Forecasted Upside-3.97% Downside-12.11% Downside-5.13% DownsideN/A
Consensus Rating
Hold
Hold
Reduce
N/A

SOLV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SOLV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Solventum Stock vs. The Competition

TypeSolventumMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-3.97% Downside27,098.21% Upside7.66% Upside
News Sentiment Rating
Positive News

See Recent SOLV News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/11/2024Morgan Stanley
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$60.00 ➝ $73.00+0.79%
11/8/2024Piper Sandler
2 of 5 stars
J. Bednar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$71.00 ➝ $75.00-0.09%
10/8/2024Stifel Nicolaus
4 of 5 stars
 Initiated CoverageBuy$82.00+23.70%
9/26/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Senyek
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoveragePeer Perform
9/5/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Zimmerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
8/12/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSell ➝ Sell$48.00 ➝ $54.00-6.56%
8/9/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$69.00 ➝ $64.00+5.66%
6/25/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$70.00 ➝ $60.00+17.26%
6/24/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
4/2/2024Edward Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:58 PM ET.


SOLV Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Solventum is $68.00, with a high forecast of $82.00 and a low forecast of $54.00.

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Solventum in the last twelve months. There is currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SOLV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SOLV, but not buy additional shares or sell existing shares.

According to analysts, Solventum's stock has a predicted downside of -3.97% based on their 12-month stock forecasts.

Solventum has been rated by research analysts at BTIG Research, Morgan Stanley, Piper Sandler, Stifel Nicolaus, and Wolfe Research in the past 90 days.

Analysts like Solventum less than other "medical" companies. The consensus rating for Solventum is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SOLV compares to other companies.


This page (NYSE:SOLV) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners